Date: 2013-04-18
Type of information: Fundraising
Company: Actogenix (Belgium)
Investors: Saffelberg Investments (Belgium) Gimv (Belgium) Biotech Fund Flanders (Belgium) Baekeland Fund (Belgium) BioVest (Belgium) LSP Life Science Partners (The Netherlands) Aescap Venture (The Netherlands) Ventech (France)
Amount: € 10.7 million
Funding type: series B financing round
Planned used: This financing round will allow ActoGeniX to execute its business strategy and fund ongoing and planned development programs.
Others: * On April 18th, 2013, ActoGeniX, a clinical stage biopharmaceutical company, has announced that it has successfully closed a Series B equity financing round, raising € 10.7 million ($ 14 million). This financing round was led by new investor Saffelberg Investments (Belgium). ActoGeniX’s founders and current investors all participated in this transaction, thus confirming their commitment to the strategic roadmap.To date, ActoGeniX raised €46.2 million ($ 60 million) in three equity financing rounds from a consortium of leading life sciences investors such as Gimv, Biotech Fund Flanders, Baekeland Fund, Biovest, Saffelberg Investments (Belgium), Life Sciences Partners, Aescap Venture (The Netherlands) and Ventech (France).
ActoGeniX is developing ActoBiotics™, a novel class of orally administered and locally acting biopharmaceuticals, in mucosal and immune diseases such as oral mucositis, inflammatory bowel disease, celiac disease, and type 1 diabetes. AG013, ActoGeniX´s lead product for the treatment of oral mucositis in cancer patients has been evaluated in a phase 1B clinical trial in the US, confirming safety and tolerability as well as initial efficacy.
Therapeutic area:
